^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Excerpt:
Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 months vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001)....Crizotinib was superior to standard first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.
DOI:
10.1056/NEJMoa1408440
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Excerpt:
...- Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagnostic test....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus (e.g....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Excerpt:
...- ≥18,Pathologically proven ALK positive mutation in advanced non squamous non small cell lung cancer...
Trial ID: